Development of a supercritical CO2 extract from Mahonia Aquifolium for use in treatment of psoriasis and eczema

加拿大生物制品公司（BCC）是一家安大略公司，开发和销售独特的专业营养和生物制品产品，用于治疗和预防常见疾病，目前的药物治疗和非处方产品无法满足患者的需求。BCC致力于成为加拿大最成功和最具创新性的生物制药公司，为客户提供最优质和最有效的天然产品。该项目将重点关注BCC目前5条产品线中的一条，称为Reliéva。Reliéva是一种抗炎皮肤治疗霜，临床证明对牛皮癣，特应性皮炎，干燥和有问题的皮肤有效。随着牛皮癣影响100万加拿大人和湿疹影响17%的加拿大人在他们的生活中的某个时候（加拿大皮肤病协会，2015），Reliéva将增加一个加拿大卫生部监管的天然产品线，目前市场上的竞争对手很少。 Reliéva含有高度浓缩的提取物，从十大功劳Aquifolium灌木，其中含有显着水平的生物碱，小檗碱。BCC已经申请了一项提取工艺的专利，将有益生物碱的浓度提高了75倍，但这个过程非常漫长。加拿大生物制品公司有必要开发更有效的提取工艺，以满足产品需求并使Reliéva商业化。本计画将探讨超临界二氧化碳萃取的有效性，以产生一种更有效的方法来萃取十大功劳中的异喹啉生物碱。超临界流体萃取（SFE）由于其无毒、不易燃、无臭、无味和成本低的特性，在天然产物中的应用急剧增加。拟议的创新提供了一个机会，开发一个更高质量的产品与更少的溶剂残留使用绿色技术，这反过来可能会转移到其他产品线的公司。加拿大生物制药公司将从该项目中受益匪浅，该项目将开发更高质量的产品，更高效，更低成本，同时使用更安全，更环保的技术。成功完成该项目后，BCC将能够开始加快Reliéva的生产，使他们能够开始与当地、国内和国际分销商签订合同。

The Canadian Bioceutical Corporation (BCC) is an Ontario corporation that develops and markets unique specialty nutraceutical and bioceutical products for the treatment and prevention of common ailments where present pharmaceutical treatments and over-the-counter products fail to meet the needs of patients. BCC is striving to become the most successful and innovative bioceutical company in Canada, providing clients with the highest quality and most efficacious natural products. This project will focus on 1 of BCCs current 5 product lines called Reliéva. Reliéva is an anti-inflammatory skin treatment cream with clinically proven effectiveness in psoriasis, atopic dermatitis, and dry and problematic skin. With psoriasis affecting 1 million Canadians and eczema affecting 17% of Canadians at some time in their life (Canadian Dermatology Association, 2015), Reliéva will add a Health Canada regulated natural product line that currently has minimal competitors on the market. Reliéva contains highly concentrated extracts from the Mahonia Aquifolium shrub, which contains significant levels of alkaloid, berberine. BCC has patented an extraction process, increasing the concentration of the beneficial alkaloids by 75 times, however the process is very lengthy. It is necessary for the Canadian Bioceutical Corporation to develop a more efficient extraction process in order to meet the product demand and commercialize Reliéva. This project will seek to determine the effectiveness of supercritical CO2 extraction to generate a more efficient method for the extraction of isoquinoline alkaloids from Mahonia aquifolium. The use of supercritical fluid extraction (SFE) has increased dramatically for use on natural products as a result of non-toxic, non-flammable, odourless and tasteless properties and low cost. The proposed innovation presents an opportunity to develop a higher quality product with less solvent residue using a green technology, which in turn may be transferred to other product lines for the company. The Canadian Bioceutical Corporation will benefit greatly from this project with the development of a higher quality product, generated more efficiently and at a lower cost, all while using a safer and more environmentally responsible technology. Upon successful completion of this project, BCC will be able to begin expedited production of Reliéva, allowing them to begin signing contracts with distributors locally, nationally and internationally.